An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
Phahol Sarojvisut, MD Anucha Apisarnthanarak, Kittiya Jantarathaneewat, Ornnicha Sathitakorn, Thanus Pienthong, Chatchai Mingmalairak, David K Warren, David J Weber
Infection & Chemotherapy, doi:10.3947/ic.2022.0127
Background: The role of ivermectin in the treatment of moderate coronavirus disease 2019 (COVID-19) is controversial. We performed an open label randomized controlled trial to evaluate the role of ivermectin plus favipiravir-based standard of care versus favipiravir-based standard of care for the treatment of moderate COVID-19 infection.
Materials and Methods: An open-label randomized control trial was performed at Thammasat Field Hospital and Thammasat University Hospital from October 1st, 2021 to May 31st, 2022. Patients with moderate COVID-19 infections were randomized to the intervention (ivermectin plus favipiravir-based standard of care) or control group (favipiravirbased standard of care alone). Patients were followed up to 21 days. The primary outcome was the improvement in World Health Organization (WHO) category ordinal scale by 2 points. Secondary outcomes included duration of illness, development of severe COVID-19, and adverse reactions. Results: There were 157 patients in the intervention and 160 patients in the control group. Characteristics, underlying diseases, and risk factors for severe COVID-19 were comparable in both groups. Improvement in the WHO-category ordinal scale by 2 points was achieved in 98.7% of the intervention group and in 99.4% of the control group (relative risk [RR]: 0.487; 95% confidence interval [CI]: 0.044-5.430). The median illness duration was 5.0 days (range, 3 -28 days) in intervention group versus 5.2 days (range, 3 -28 days) in control group (P = 0.630). Severe COVID-19 that required intensive care occurred in 2 patients (1.3%) in the intervention group and 1 patient (0.6%) in the control group (RR: 2.052; 95% CI: 0.184 -22.857). No significant difference in serious drug adverse events was seen.
SUPPLEMENTARY MATERIAL Supplementary
References
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis,
doi:10.1016/j.ijid.2020.11.191Bhimraj, Morgan, Shumaker, Baden, Cheng et al., Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19, Infectious Diseases Society of America
Bramante, Huling, Tignanelli, Buse, Liebovitz et al., Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2201662Cevik, Kuppalli, Kindrachuk, Peiris, Virology, transmission, and pathogenesis of SARS-CoV-2, BMJ,
doi:10.1136/bmj.m3862Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., None
Chen, Feng, Xu, Huang, Sun et al., Patterns of deterioration in moderate patients with COVID-19 from Jan 2020 to Mar 2020: a multi-center, retrospective cohort study in China, Front Med,
doi:10.3389/fmed.2020.567296Chowdhury, Shahbaz, Karim, Islam, Dan et al., A comparative study on ivermectindoxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients, EJMO,
doi:10.14744/ejmo.2021.16263Karatas, Aksoy, Ozaslan, Association of early favipiravir use with reduced COVID-19 fatality among hospitalized patients, Infect Chemother,
doi:10.3947/ic.2020.0149Kim, Ryoo, Huh, Joo, Kim et al., Revised Korean Society of Infectious Diseases/national evidence-based healthcarea collaborating agency guidelines on the treatment of patients with COVID-19, Infect Chemother,
doi:10.3947/ic.2021.0303Lifschitz, Virkel, Sallovitz, Sutra, Galtier et al., Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle, Vet Parasitol,
doi:10.1016/S0304-4017(99)00175-2Lim, Hor, Tay, Jelani, Tan et al., Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: The I-TECH randomized clinical trial, JAMA Intern Med,
doi:10.1001/jamainternmed.2022.0189López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2021.3071Marcolino, Meira, Guimarães, Motta, Chagas et al., Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype, BMC Infect Dis,
doi:10.1186/s12879-022-07589-8Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world effectiveness and optimal dosage of favipiravir for treatment of COVID-19: results from a multicenter observational study in Thailand, Antibiotics,
doi:10.3390/antibiotics11060805Reina, Sadaba, Fernández-Alonso, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebocontrolled, randomized clinical trial, EClinicalMedicine,
doi:10.1016/j.eclinm.2020.100720Reis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with ivermectin among patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2115869Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther,
doi:10.1002/cpt.1889Sirijatuphat, Suputtamongkol, Angkasekwinai, Horthongkham, Chayakulkeeree et al., Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital, BMC Infect Dis,
doi:10.1186/s12879-021-06081-zWagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J,
doi:10.1042/BJ20120150Working, Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect Dis,
doi:10.1016/S1473-3099(20)30483-7Özlüşen, Kozan, Akcan, Kalender, Yaprak et al., Effectiveness of favipiravir in COVID-19: a live systematic review, Eur J Clin Microbiol Infect Dis,
doi:10.1007/s10096-021-04307-1DOI record:
{
"DOI": "10.3947/ic.2022.0127",
"ISSN": [
"2093-2340",
"2092-6448"
],
"URL": "http://dx.doi.org/10.3947/ic.2022.0127",
"assertion": [
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Received",
"name": "received",
"value": "2022-08-08"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Accepted",
"name": "accepted",
"value": "2022-10-03"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Published online",
"name": "published_online",
"value": "2022-12-12"
},
{
"group": {
"label": "Copyright and Licensing",
"name": "Copyright_and_licensing"
},
"label": "Copyright",
"name": "copyright",
"value": "Copyright © 2022 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS"
},
{
"explanation": {
"URL": "https://creativecommons.org/licenses/by-nc/4.0/"
},
"group": {
"label": "Copyright and Licensing",
"name": "Copyright_and_licensing"
},
"label": "License",
"name": "license",
"value": "This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited."
}
],
"author": [
{
"ORCID": "http://orcid.org/0000-0001-5152-1752",
"affiliation": [
{
"name": "Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand."
}
],
"authenticated-orcid": false,
"family": "Sarojvisut",
"given": "Phahol",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0001-6390-9519",
"affiliation": [
{
"name": "Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand."
},
{
"name": "Research group in Infectious Diseases Epidemiology and Prevention, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand."
}
],
"authenticated-orcid": false,
"family": "Apisarnthanarak",
"given": "Anucha",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-9428-6131",
"affiliation": [
{
"name": "Research group in Infectious Diseases Epidemiology and Prevention, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand."
},
{
"name": "Center of Excellence in Pharmacy Practice and Management Research, Faculty of Pharmacy, Thammasat University, Pathum Thani, Thailand."
}
],
"authenticated-orcid": false,
"family": "Jantarathaneewat",
"given": "Kittiya",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-2347-6074",
"affiliation": [
{
"name": "Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand."
}
],
"authenticated-orcid": false,
"family": "Sathitakorn",
"given": "Ornnicha",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-6859-9118",
"affiliation": [
{
"name": "Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand."
}
],
"authenticated-orcid": false,
"family": "Pienthong",
"given": "Thanus",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-8596-5378",
"affiliation": [
{
"name": "Department of Surgery, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand."
}
],
"authenticated-orcid": false,
"family": "Mingmalairak",
"given": "Chatchai",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-8679-8241",
"affiliation": [
{
"name": "Division of Infectious Diseases, Washington University School of Medicine, St.Louis, MO, USA."
}
],
"authenticated-orcid": false,
"family": "Warren",
"given": "David K",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-8824-1110",
"affiliation": [
{
"name": "Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA."
}
],
"authenticated-orcid": false,
"family": "Weber",
"given": "David J",
"sequence": "additional"
}
],
"container-title": "Infection & Chemotherapy",
"container-title-short": "Infect Chemother",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"icjournal.org"
]
},
"created": {
"date-parts": [
[
2022,
12,
14
]
],
"date-time": "2022-12-14T23:58:06Z",
"timestamp": 1671062286000
},
"deposited": {
"date-parts": [
[
2022,
12,
14
]
],
"date-time": "2022-12-14T23:58:41Z",
"timestamp": 1671062321000
},
"indexed": {
"date-parts": [
[
2022,
12,
15
]
],
"date-time": "2022-12-15T07:14:45Z",
"timestamp": 1671088485756
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2022
]
]
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by-nc/4.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
1,
1
]
],
"date-time": "2022-01-01T00:00:00Z",
"timestamp": 1640995200000
}
}
],
"link": [
{
"URL": "https://icjournal.org/pdf/10.3947/ic.2022.0127",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://icjournal.org/DOIx.php?id=10.3947/ic.2022.0127",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://icjournal.org/DOIx.php?id=10.3947/ic.2022.0127",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "2343",
"original-title": [],
"prefix": "10.3947",
"published": {
"date-parts": [
[
2022
]
]
},
"published-online": {
"date-parts": [
[
2022
]
]
},
"publisher": "Korean Society of Infectious Diseases and Korean Society for Chemotherapy",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://icjournal.org/DOIx.php?id=10.3947/ic.2022.0127"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Pharmacology (medical)",
"Infectious Diseases"
],
"subtitle": [],
"title": "An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.3947/crossmark_policy",
"volume": "54"
}
